Stock of Jade Biosciences, Inc. (JBIO) is dropping about 12 percent in Monday morning trading despite the company's positive report from a Phase 1 trial evaluating JADE101 for the treatment of immunoglobulin A nephropathy.
The company's stock is currently trading at $18.35, down 12.77 percent or $2.69, over the previous close of $21.04 on the Nasdaq. It has traded between $6.57 and $28.00 in the past one year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.